Susquehanna International Group
ITOS

Susquehanna International Group’s iTeos Therapeutics ITOS Stock Holding History

Susquehanna International Group’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-106,400
Closed -$1.06M – 13148
2025
Q2 		$1.06M Buy
+106,400
New +$857K ﹤0.01% 7260
2025
Q1 		– Sell
-71,000
Closed -$545K – 12966
2024
Q4 		$545K Sell
71,000
-34,500
-33% -$296K ﹤0.01% 8459
2024
Q3 		$1.08M Sell
105,500
-73,000
-41% -$1.11M ﹤0.01% 6619
2024
Q2 		$2.65M Buy
178,500
+153,700
+620% +$2.2M ﹤0.01% 4541
2024
Q1 		$338K Sell
24,800
-82,600
-77% -$900K ﹤0.01% 9434
2023
Q4 		$1.18M Sell
107,400
-2,800
-3% -$27.8K ﹤0.01% 6591
2023
Q3 		$1.21M Buy
+110,200
New +$1.41M ﹤0.01% 6216
2023
Q2 		– Sell
-22,300
Closed -$304K – 12601
2023
Q1 		$304K Buy
+22,300
New +$400K ﹤0.01% 9693
2022
Q3 		– Sell
-47,600
Closed -$981K – 13650
2022
Q2 		$981K Buy
47,600
+37,800
+386% +$897K ﹤0.01% 6579
2022
Q1 		$315K Buy
+9,800
New +$356K ﹤0.01% 10153

Other funds holding ITOS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's ITOS Position: Q3 2025 in Review

Susquehanna International Group sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 144,080 shares — an estimated $1.44M sold.

Susquehanna International Group first reported a position in ITOS in Q1 2021 and held it in 17 quarters. The position peaked at $3.58M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • Susquehanna International Group reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 144,080 iTeos Therapeutics shares in Q3 2025, an estimated $1.44M.
  • Susquehanna International Group first reported a position in iTeos Therapeutics in Q1 2021 and held it in 17 quarters.
  • Susquehanna International Group's iTeos Therapeutics position peaked at $3.58M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.